{"nctId":"NCT04602000","briefTitle":"A Phase 2/3 Study to Evaluate the Efficacy and Safety of CT-P59 in Patients With Mild to Moderate SARS-CoV-2 Infection","startDateStruct":{"date":"2020-10-05","type":"ACTUAL"},"conditions":["SARS-CoV-2 Infection"],"count":1642,"armGroups":[{"label":"CT-P59 40 mg/kg group (Part 1)","type":"EXPERIMENTAL","interventionNames":["Biological: CT-P59"]},{"label":"CT-P59 80 mg/kg group (Part 1)","type":"EXPERIMENTAL","interventionNames":["Biological: CT-P59"]},{"label":"Placebo group (Part 1)","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo"]},{"label":"CT-P59 40 mg/kg group (Part 2)","type":"EXPERIMENTAL","interventionNames":["Biological: CT-P59"]},{"label":"Placebo group (Part 2)","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo"]}],"interventions":[{"name":"CT-P59","otherNames":["regdanvimab"]},{"name":"CT-P59","otherNames":["regdanvimab"]},{"name":"Placebo","otherNames":[]},{"name":"CT-P59","otherNames":["regdanvimab"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nPatient had to meet all of the following criteria to be randomized in this study.\n\n1. Patient was an adult male or female patient, aged 18 or above.\n2. Patient was diagnosed with SARS-CoV-2 infection at Screening by using the sponsor-supplied rapid SARS-CoV-2 diagnostic test or RT-PCR (reverse transcription-polymerase chain reaction).\n3. Patient with conditions meeting all of the following criteria:\n\n   1. Oxygen saturation \\> 94% on room air.\n   2. Not requiring supplemental oxygen.\n4. Patient who had an onset of symptom no more than 7 days prior to the study drug administration.\n5. Patient had 1 or more of the SARS-CoV-2 infection-associated symptoms within but no more than 7 days prior to the study drug administration.\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria were excluded from the study.\n\n1. Patient had current severe condition meeting one of the following:\n\n   1. Previous or current hospitalization or requirement of hospitalization for treatment of serious SARS-CoV-2 related conditions.\n   2. Respiratory distress with respiratory rate â‰¥30 breaths/min.\n   3. Required supplemental oxygen\n   4. Experienced shock\n   5. Complicated with other organs failure, and intensive care unit monitoring treatment is needed by investigator's discretion.\n2. Patient had received or had a plan to receive any of the following prohibited medications or treatments:\n\n   1. Drugs with actual or possible antiviral drugs and/or possible anti-SARS-CoV-2 activity including but not limited to remdesivir, chloroquine, hydroxychloroquine, dexamethasone (or alternative corticosteroids to dexamethasone), interferon beta-1b, ribavirin, and other immunomodulatory agents and human immunodeficiency virus protease inhibitors (lopinavir-ritonavir, etc.) for therapeutic purpose of SARS-CoV-2 infection prior to study drug administration\n   2. Any SARS-CoV-2 human IV immunoglobulin, convalescent plasma for the treatment of SARS-CoV-2 infection prior to study drug administration\n   3. Any other investigational device or medical product including but not limited to any monoclonal antibody (tocilizumab, sarilumab, etc.), fusion proteins or biologics for the treatment of SARS-CoV-2 infection prior to the study drug administration\n   4. Use of medications that are contraindicated with SoC\n   5. SARS-CoV-2 vaccine prior to the study drug administration","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Patients With Clinical Symptom Requiring Hospitalization, Oxygen Therapy, or Experiencing Mortality Due to SARS-CoV-2 Infection (Part 1)","description":"To assess the clinically meaningful therapeutic efficacy of CT-P59 as determined by proportion of patients with clinical symptom requiring hospitalization, oxygen therapy, or experiencing mortality due to SARS-CoV-2 infection up to Day 28","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]}]},{"type":"PRIMARY","title":"Proportion of Patients With Negative Conversion in Nasopharyngeal Swab Specimen Based on RT-qPCR at Each Visit (Part 1)","description":"To assess the potential therapeutic efficacy of CT-P59 as determined by proportion of negative conversion in nasopharyngeal swab specimen based on RT-qPCR up to Day 14","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"23","spread":null}]}]}]},{"type":"PRIMARY","title":"Time to Negative Conversion in Nasopharyngeal Swab Specimen (Part 1)","description":"To evaluate the therapeutic efficacy of CT-P59 as determined by time to negative conversion by RT-qPCR up to Day 14","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.75","spread":null},{"groupId":"OG001","value":"11.89","spread":null},{"groupId":"OG002","value":"12.94","spread":null}]}]}]},{"type":"PRIMARY","title":"Time to Clinical Recovery (Part 1)","description":"To assess the potential therapeutic efficacy of CT-P59 as determined by time to clinical recovery up to Day 14.\n\nClinical recovery was defined as all symptoms on the SARS-CoV-2 Infection Symptom Checklist 1 being recorded as 'absent' or 'mild' in intensity for at least 48 hours. SARS-CoV-2 Infection Symptom Checklist 1 consisted of 7 symptoms (feeling feverish, cough, shortness of breath or difficulty breathing, sore throat, body pain or muscle pain, fatigue, and headache) and the intensity of patient's self-aware for each SARS-CoV-2 infection symptom (absent \\[0\\], mild \\[1\\]. moderate \\[2\\], and severe \\[3\\]).\n\nTo meet the clinical recovery, symptoms 'severe' or 'moderate' in intensity at baseline should be changed to 'mild' or 'absent', or symptoms 'mild' in intensity at baseline should be changed to 'absent', after the study drug administration. Symptoms \"absent\" in intensity at baseline should maintain as \"absent\" for at least 48 hours.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.18","spread":null},{"groupId":"OG001","value":"7.30","spread":null},{"groupId":"OG002","value":"8.80","spread":null}]}]}]},{"type":"PRIMARY","title":"Proportion of Patients With Clinical Symptom Requiring Hospitalization, Oxygen Therapy, or Experiencing Mortality Due to SARS-CoV-2 Infection up to Day 28 in High-risk Patients (Part 2)","description":"To demonstrate the clinically meaningful therapeutic efficacy of CT-P59 as determined by proportion of patients with clinical symptom requiring hospitalization, oxygen therapy, or experiencing mortality due to SARS-CoV-2 infection up to Day 28 in high-risk patients","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With Clinical Symptom Requiring Hospitalization, Oxygen Therapy, or Experiencing Mortality Due to SARS-CoV-2 Infection up to Day 28 in All Randomized Patients (Part 2)","description":"To demonstrate the clinically meaningful therapeutic efficacy of CT-P59 as determined by proportion of patients with clinical symptom requiring hospitalization, oxygen therapy, or experiencing mortality due to SARS-CoV-2 infection up to Day 28 in all randomized patients","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Clinical Recovery up to Day 14 in High-risk Patients (Part 2)","description":"To assess the potential therapeutic efficacy of CT-P59 as determined by time to clinical recovery up to Day 14 in high-risk patients.\n\nClinical recovery was defined as all symptoms on the SARS-CoV-2 Infection Symptom Checklist 1 being recorded as 'absent' or 'mild' in intensity for at least 48 hours. SARS-CoV-2 Infection Symptom Checklist 1 consisted of 7 symptoms (feeling feverish, cough, shortness of breath or difficulty breathing, sore throat, body pain or muscle pain, fatigue, and headache) and the intensity of patient's self-aware for each SARS-CoV-2 infection symptom (absent \\[0\\], mild \\[1\\]. moderate \\[2\\], and severe \\[3\\]).\n\nTo meet the clinical recovery, symptoms 'severe' or 'moderate' in intensity at baseline should be changed to 'mild' or 'absent', or symptoms 'mild' in intensity at baseline should be changed to 'absent', after the study drug administration. Symptoms \"absent\" in intensity at baseline should maintain as \"absent\" for at least 48 hours.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.27","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Clinical Recovery up to Day 14 in All Randomized Patients (Part 2)","description":"To assess the potential therapeutic efficacy of CT-P59 as determined by time to clinical recovery up to Day 14 in all randomized patients.\n\nClinical recovery was defined as all symptoms on the SARS-CoV-2 Infection Symptom Checklist 1 being recorded as 'absent' or 'mild' in intensity for at least 48 hours. SARS-CoV-2 Infection Symptom Checklist 1 consisted of 7 symptoms (feeling feverish, cough, shortness of breath or difficulty breathing, sore throat, body pain or muscle pain, fatigue, and headache) and the intensity of patient's self-aware for each SARS-CoV-2 infection symptom (absent \\[0\\], mild \\[1\\]. moderate \\[2\\], and severe \\[3\\]).\n\nTo meet the clinical recovery, symptoms 'severe' or 'moderate' in intensity at baseline should be changed to 'mild' or 'absent', or symptoms 'mild' in intensity at baseline should be changed to 'absent', after the study drug administration. Symptoms \"absent\" in intensity at baseline should maintain as \"absent\" for at least 48 hours.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.38","spread":null},{"groupId":"OG001","value":"13.25","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With Hospital Admission Due to SARS-CoV-2 Infection (Part 1 and Part 2)","description":"To evaluate the additional efficacy of CT-P59","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"16","spread":null},{"groupId":"OG004","value":"52","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients Requiring Supplemental Oxygen Due to SARS-CoV-2 Infection (Part 1 and Part 2)","description":"To evaluate the additional efficacy of CT-P59","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"15","spread":null},{"groupId":"OG004","value":"49","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With Mechanical Ventilation Use Due to SARS-CoV-2 Infection (Part 1 and Part 2)","description":"To evaluate the additional efficacy of CT-P59","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients Requiring Rescue Therapy Due to SARS-CoV-2 Infection (Part 1 and Part 2)","description":"To evaluate the additional efficacy of CT-P59","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"15","spread":null},{"groupId":"OG003","value":"37","spread":null},{"groupId":"OG004","value":"85","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With Intensive Care Unit Transfer Due to SARS-CoV-2 Infection (Part 1 and Part 2)","description":"To evaluate the additional efficacy of CT-P59","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With All-cause Mortality (Part 1 and Part 2)","description":"To evaluate the additional efficacy of CT-P59","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Negative Conversion in Nasopharyngeal Swab Specimen Based on RT-qPCR (Part 1 and Part 2)","description":"To evaluate the additional efficacy of CT-P59","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.75","spread":null},{"groupId":"OG001","value":"11.89","spread":null},{"groupId":"OG002","value":"12.94","spread":null},{"groupId":"OG003","value":"11.90","spread":null},{"groupId":"OG004","value":"13.15","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patient With Negative Conversion in Nasopharyngeal Swab Specimen Based on RT-qPCR at Each Visit (Part 1 and Part 2)","description":"To evaluate the additional efficacy of CT-P59","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"34","spread":null},{"groupId":"OG004","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"141","spread":null},{"groupId":"OG004","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"19","spread":null},{"groupId":"OG003","value":"137","spread":null},{"groupId":"OG004","value":"117","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"23","spread":null},{"groupId":"OG003","value":"113","spread":null},{"groupId":"OG004","value":"149","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"99","spread":null},{"groupId":"OG004","value":"117","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"52","spread":null},{"groupId":"OG004","value":"61","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Clinical Recovery (Part 1 and Part 2)","description":"To evaluate the additional efficacy of CT-P59. Clinical recovery was defined as all symptoms on the SARS-CoV-2 Infection Symptom Checklist 1 being recorded as 'absent' or 'mild' in intensity for at least 48 hours. SARS-CoV-2 Infection Symptom Checklist 1 consisted of 7 symptoms (feeling feverish, cough, shortness of breath or difficulty breathing, sore throat, body pain or muscle pain, fatigue, and headache) and the intensity of patient's self-aware for each SARS-CoV-2 infection symptom (absent \\[0\\], mild \\[1\\]. moderate \\[2\\], and severe \\[3\\]).\n\nTo meet the clinical recovery, symptoms 'severe' or 'moderate' in intensity at baseline should be changed to 'mild' or 'absent', or symptoms 'mild' in intensity at baseline should be changed to 'absent', after the study drug administration. Symptoms \"absent\" in intensity at baseline should maintain as \"absent\" for at least 48 hours.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.18","spread":null},{"groupId":"OG001","value":"7.30","spread":null},{"groupId":"OG002","value":"8.80","spread":null},{"groupId":"OG003","value":"8.39","spread":null},{"groupId":"OG004","value":"13.29","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"[Virology] Viral Serology for SARS-CoV-2 Antibody","description":"To assess the serology of SARS-CoV-2 antibody. The proportions of patients positive with IgG or IgM were summarized.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"45","spread":null},{"groupId":"OG004","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"32","spread":null},{"groupId":"OG003","value":"354","spread":null},{"groupId":"OG004","value":"322","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"86","spread":null},{"groupId":"OG003","value":"498","spread":null},{"groupId":"OG004","value":"509","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"94","spread":null},{"groupId":"OG002","value":"91","spread":null},{"groupId":"OG003","value":"535","spread":null},{"groupId":"OG004","value":"548","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"85","spread":null},{"groupId":"OG002","value":"86","spread":null},{"groupId":"OG003","value":"506","spread":null},{"groupId":"OG004","value":"532","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"53","spread":null},{"groupId":"OG004","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"43","spread":null},{"groupId":"OG002","value":"49","spread":null},{"groupId":"OG003","value":"362","spread":null},{"groupId":"OG004","value":"332","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"87","spread":null},{"groupId":"OG003","value":"467","spread":null},{"groupId":"OG004","value":"491","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"77","spread":null},{"groupId":"OG002","value":"65","spread":null},{"groupId":"OG003","value":"461","spread":null},{"groupId":"OG004","value":"493","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"54","spread":null},{"groupId":"OG002","value":"51","spread":null},{"groupId":"OG003","value":"407","spread":null},{"groupId":"OG004","value":"441","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"[PK] Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) (Part 1)","description":"To assess the PK of CT-P59","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"212460.507","spread":"46724.5556"},{"groupId":"OG001","value":"426694.643","spread":"121171.182"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"[PK] Maximum Serum Concentration (Cmax) (Part 1)","description":"To assess the PK of CT-P59","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1016.6","spread":"268.97"},{"groupId":"OG001","value":"2007.6","spread":"477.97"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"[PK] Terminal Half-life (t1/2) (Part 1)","description":"To assess the PK of CT-P59","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"403.916","spread":"147.8450"},{"groupId":"OG001","value":"453.442","spread":"107.5620"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":105},"commonTop":["Hypertriglyceridaemia","Alanine aminotransferase increased","Hepatic enzyme increased","Inflammatory marker increased","Hypertension"]}}}